This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De La Cochetière, M. F.
Right arrow Articles by Doré, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De La Cochetière, M. F.
Right arrow Articles by Doré, J.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 2005, p. 5588-5592, Vol. 43, No. 11
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.11.5588-5592.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Resilience of the Dominant Human Fecal Microbiota upon Short-Course Antibiotic Challenge

M. F. De La Cochetière,1* T. Durand,1 P. Lepage,2 A. Bourreille,1,3 J. P. Galmiche,1,3 and J. Doré2

INSERM Unité 539 CHU Hôtel-Dieu, Place Alexis Ricordeau, 44035 Nantes cedex 1, France,1 INRA, CR de Jouy en Josas, 78352 Jouy en Josas, France,2 Department of Hepatogastroenterology and Nutritional Support, CHU Place Alexis Ricordeau, 44035 Nantes cedex 1, France3

Received 11 March 2005/ Returned for modification 1 June 2005/ Accepted 1 August 2005

Recent studies have shown that the human fecal microbiota is composed of a consortium of species specific to the host and resistant to modifications over time. Antibiotics are known to affect the intestinal microflora, and ensuing changes may result in antibiotic-associated diarrhea. It is therefore important to characterize the nature and amplitude of these modifications and the ability of this ecosystem to return to its original profile—i.e., its resilience. Six healthy volunteers received oral amoxicillin (1.5 g/day) for 5 days. Fecal samples were collected at day 0 (D0) before antibiotic treatment and at set intervals until 60 days thereafter. Fecal DNA was isolated, and V6-to-V8 regions of the 16S rRNA genes were amplified by PCR with general primers and analyzed by temporal temperature gradient gel electrophoresis. Dominant species profiles were compared on the basis of similarity (Pearson correlation coefficient). Dominant species profiles at D0 were used as a reference. The fecal microbiota showed a major shift in dominant species upon antibiotic treatment, starting 24 h after treatment initiation and reaching an average similarity of only 74% after 4 days. Within 30 days following antibiotic treatment, the fecal microbiota tended to reach an average similarity of 88% to the D0 value; within 60 days, the average similarity to the D0 value was 89%. However, in one subject, important modifications persisted for at least 2 months, with similarity to the D0 value remaining below 70%. We demonstrated the resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. Yet the persistence of long-term alterations in some subjects may explain susceptibilities to antibiotic-associated diarrhea. Furthermore, these findings suggest that strategies reinforcing the ability of the fecal microbiota to resist modifications would be of clinical relevance.

* Corresponding author. Mailing address: INSERM Unité 539 CHU Hôtel-Dieu, Place Alexis Ricordeau, 44035 Nantes cedex 1, France. Phone: 33 (0)2 40 08 75 10. Fax: 33 (0)2 40 08 75 06. E-mail: mfdlc{at}nantes.inserm.fr.

Journal of Clinical Microbiology, November 2005, p. 5588-5592, Vol. 43, No. 11
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.11.5588-5592.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Jacquot, A, Labaune, J-M, Baum, T-P, Putet, G, Picaud, J-C (2009). Rapid quantitative procalcitonin measurement to diagnose nosocomial infections in newborn infants. Arch. Dis. Child. Fetal Neonatal Ed. 94: F345-F348 [Abstract] [Full Text]  
  • Zhang, H., DiBaise, J. K., Zuccolo, A., Kudrna, D., Braidotti, M., Yu, Y., Parameswaran, P., Crowell, M. D., Wing, R., Rittmann, B. E., Krajmalnik-Brown, R. (2009). Human gut microbiota in obesity and after gastric bypass. Proc. Natl. Acad. Sci. USA 106: 2365-2370 [Abstract] [Full Text]  
  • Whelan, K., Judd, P. A, Tuohy, K. M, Gibson, G. R, Preedy, V. R, Taylor, M. A (2009). Fecal microbiota in patients receiving enteral feeding are highly variable and may be altered in those who develop diarrhea. Am. J. Clin. Nutr. 89: 240-247 [Abstract] [Full Text]  
  • Mai, V., Braden, C. R., Heckendorf, J., Pironis, B., Hirshon, J. M. (2006). Monitoring of Stool Microbiota in Subjects with Diarrhea Indicates Distortions in Composition. J. Clin. Microbiol. 44: 4550-4552 [Abstract] [Full Text]  
  • Scanlan, P. D., Shanahan, F., O'Mahony, C., Marchesi, J. R. (2006). Culture-Independent Analyses of Temporal Variation of the Dominant Fecal Microbiota and Targeted Bacterial Subgroups in Crohn's Disease. J. Clin. Microbiol. 44: 3980-3988 [Abstract] [Full Text]  
  • (2006). Short-Course Antibiotic Therapy, Long-Term Impact. JWatch Infect. Diseases 2006: 8-8 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»